P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B‐CELL LYMPHOMA

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 7; no. S3; pp. e68510b0 - n/a
Main Authors Yang, Fan, Liu, Rui, Fu, Zhonghua, Xu, Teng, Zheng, Peihao, Feng, Shaomei, Guo, Yuelu, MA, Lixia, Shi, Hui, Deng, Biping, Ke, Xiaoyan, Hu, Kai
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 08.08.2023
Wiley
Online AccessGet full text

Cover

More Information
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000971588.68510.b0